Samarth Jain, Founder & CEO, Positive Biosciences feels genetic education for oncologists is necessary to build their capacity of understanding

Positive Bioscience, India’s leading clinical genomics company using big data & artificial intelligence to predict disease risk in healthy individuals and best treatment options in cancer patients, launched Positive – Academy for Training in Genomics and Clinical applications (ATGC), an initiative to help oncologists gain competency at using genomics in their practice.

The initiative will be rolled out across the country in association with ICON and MOS (Molecular Oncology Society).

Dr Purvish M Parikh, President of Molecular Oncology Society and Director of Precision Oncology at Asian Cancer Institute has underlined the importance of in-depth genetic testing

Positive ATGC “ Key Takeaways

• Will conduct regular workshops in Delhi, Hyderabad, Bengaluru & Mumbai.
• Will award participants with a certificate accepted as continuing medical education (CME).
• Has been designed to enhance the education of clinical oncology professionals on the topics of cancer genomics, cancer risk assessment, and application of precision medicine in clinical practice.
• Will include topics on technology and equipment, understanding and applying genomic report to clinical practice, as well as the concept of pathways and its utility in clinical practice.
• Will also conduct six-month training programs on genomics for doctors.
• The training will be certified by a leading medical university.
• Will publish periodic newsletters for updating Oncologists with the latest developments in genomic technology.
• Aims to reach out to over 200+ doctors by 2017.

Cancer is being relooked on the basis of driver mutations

Why genetic testing for cancer?

In order to ensure right drug at the very first instance, doctors need a proper understanding of the tumour and normal metabolism of the patient, which is only possible through an in-depth genetic testing. Due to the increased focus on precision oncology & personalized medicine, the entire oncology as one of the healthcare segments has witnessed a major paradigm shift, i.e. transition from the classification of cancer on the basis of the organ of origin to determining the nature of cancer by relooking at driver mutations.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.